Makoto Shibutani Selected Research

Fenbendazole

8/2010	Disruption of Smad-dependent signaling for growth of GST-P-positive lesions from the early stage in a rat two-stage hepatocarcinogenesis model.
4/2010	Induction of GST-P-positive proliferative lesions facilitating lipid peroxidation with possible involvement of transferrin receptor up-regulation and ceruloplasmin down-regulation from the early stage of liver tumor promotion in rats.
5/2009	Crosstalk between PTEN/Akt2 and TGFbeta signaling involving EGF receptor down-regulation during the tumor promotion process from the early stage in a rat two-stage hepatocarcinogenesis model.
11/2008	Cellular distributions of molecules with altered expression specific to the tumor promotion process from the early stage in a rat two-stage hepatocarcinogenesis model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Makoto Shibutani Research Topics

Disease

77	Neoplasms (Cancer) 01/2022 - 01/2002
22	Carcinogenesis 01/2021 - 01/2002
21	Body Weight (Weight, Body) 01/2022 - 07/2007
13	Hypothyroidism 07/2019 - 12/2007
8	Carcinoma (Carcinomatosis) 03/2013 - 01/2002
6	Colorectal Neoplasms (Colorectal Cancer) 10/2021 - 08/2012
6	Inflammation (Inflammations) 09/2017 - 04/2011
5	Adenoma (Adenomas) 10/2017 - 12/2009
4	AIDS-Related Complex (ARC) 10/2021 - 08/2015
4	Colonic Neoplasms (Colon Cancer) 05/2018 - 12/2013
4	Colitis 10/2017 - 02/2017
4	Hypertrophy 01/2011 - 02/2007
3	Neuroinflammatory Diseases 05/2022 - 10/2021
3	Autistic Disorder (Autism) 01/2022 - 01/2017
3	Necrosis 04/2017 - 01/2008
3	Hyperplasia 05/2010 - 03/2005
2	Obesity 01/2019 - 01/2018
2	Anorexia 07/2018 - 09/2017
2	Lethargy 07/2018 - 09/2017
2	Aberrant Crypt Foci 10/2017 - 01/2017
2	Hepatocellular Carcinoma (Hepatoma) 01/2017 - 06/2002
2	Edema (Dropsy) 02/2016 - 02/2015
2	Microcephaly 05/2014 - 04/2014
2	Thyroid Neoplasms (Thyroid Cancer) 06/2012 - 01/2012

Drug/Important Bio-Agent (IBA)

15	Drinking WaterIBA 01/2022 - 07/2009
15	Proteins (Proteins, Gene)FDA Link 07/2019 - 06/2002
12	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 10/2019 - 07/2007
11	AntioxidantsIBA 01/2022 - 01/2002
11	Phenobarbital (Luminal)FDA Link 02/2014 - 06/2002
10	isoquercitrinIBA 01/2022 - 02/2010
8	Thioacetamide (Thioacetamid)IBA 10/2019 - 05/2009
8	Keratins (Keratin)IBA 07/2018 - 02/2010
8	Propylthiouracil FDA Link 11/2016 - 12/2007
8	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2016 - 01/2011
7	CarcinogensIBA 01/2021 - 06/2002
7	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2017 - 05/2008
7	Piperonyl Butoxide FDA Link 08/2014 - 05/2009
6	VimentinIBA 04/2018 - 06/2010
6	Methimazole (Thiamazole)FDA LinkGeneric 03/2015 - 12/2007
5	CytokinesIBA 01/2022 - 05/2010
5	AzoxymethaneIBA 05/2018 - 05/2015
5	indole-3-carbinolIBA 02/2014 - 01/2011
5	SulfadimethoxineIBA 03/2013 - 04/2009
5	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2012 - 02/2010
5	EnzymesIBA 01/2012 - 12/2008
4	Proliferating Cell Nuclear Antigen (PCNA)IBA 07/2021 - 02/2010
4	Thioctic Acid (Lipoic Acid)IBA 07/2019 - 09/2013
4	Dextrans (Dextran)FDA Link 05/2018 - 02/2017
4	SodiumIBA 10/2017 - 03/2005
4	FenbendazoleIBA 08/2010 - 11/2008
3	CateninsIBA 10/2022 - 05/2015
3	Ethanol (Ethyl Alcohol)IBA 05/2022 - 04/2006
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 04/2011
3	Dihydrotachysterol (AT 10)IBA 08/2019 - 06/2013
3	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2019 - 08/2010
3	Indocyanine Green (Cardio-Green)FDA LinkGeneric 05/2018 - 01/2016
3	Phosphotransferases (Kinase)IBA 10/2017 - 05/2009
3	Chromogranin AIBA 03/2017 - 09/2010
3	SynaptophysinIBA 11/2016 - 03/2009
3	ParvalbuminsIBA 08/2015 - 10/2012
3	TenascinIBA 12/2013 - 06/2012
3	Antithyroid Agents (Antithyroid Drugs)IBA 03/2013 - 12/2007
3	Hormones (Hormone)IBA 09/2012 - 01/2003
3	nivalenolIBA 06/2012 - 01/2008
3	Messenger RNA (mRNA)IBA 09/2011 - 12/2008
3	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 05/2010 - 07/2009
2	Dextran SulfateIBA 10/2022 - 09/2017
2	acetamideIBA 01/2021 - 10/2020
2	Pharmaceutical PreparationsIBA 10/2020 - 01/2012
2	Carbon Tetrachloride (Tetrachloromethane)IBA 10/2019 - 08/2011
2	Valproic Acid (Depakote)FDA LinkGeneric 09/2019 - 01/2017
2	Periodic AcidIBA 07/2018 - 05/2015
2	CAM 5.2 antigenIBA 07/2018 - 06/2017
2	Biological ProductsIBA 07/2018 - 03/2009
2	NestinIBA 04/2018 - 03/2009
2	Protein Kinases (Protein Kinase)IBA 10/2017 - 09/2017
2	Inhibins (Inhibin)IBA 06/2017 - 02/2010
2	Cilostazol (Pletal)FDA LinkGeneric 04/2017 - 02/2017
2	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 03/2017 - 11/2016
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 06/2002
2	Protoporphyrinogen Oxidase (Protox)IBA 01/2017 - 01/2016
2	Phosphopyruvate Hydratase (Enolase)IBA 11/2016 - 02/2010
2	DesminIBA 11/2016 - 05/2012
2	Hexachlorophene FDA LinkGeneric 02/2016 - 02/2015
2	Thyroid HormonesIBA 08/2014 - 06/2013
2	TensinsIBA 08/2014 - 05/2009
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 08/2014 - 05/2009
2	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 05/2014 - 04/2014
2	Alkylating AgentsIBA 05/2014 - 04/2014
2	ParaffinIBA 02/2014 - 04/2006
2	diisopropanolnitrosamineIBA 03/2013 - 07/2009
2	Orphenadrine (Disipal)FDA LinkGeneric 01/2013 - 01/2013
2	Aminobutyrates (Aminobutyric Acid)IBA 10/2012 - 08/2011
2	Carmine (Natural Red 4)IBA 06/2012 - 01/2012

Therapy/Procedure

9	Intraperitoneal Injections 09/2017 - 07/2007
2	Drug Therapy (Chemotherapy) 10/2021 - 01/2021
2	Hepatectomy 01/2019 - 02/2010
2	Oral Administration 07/2018 - 10/2009
2	Chemoprevention 01/2017 - 01/2002
2	Aftercare (After-Treatment) 05/2015 - 04/2010